eligibility for glp 1 If you're covered by the State Health Benefit Plan (SHBP) and take a weight-loss GLP-1 medication (like Wegovy or Zepbound), a change is coming. Starting February 1, 2026, SHBP will require these qualifications for glp-1 meds GLP-1

Description

Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself

[DOI] [PubMed] [Google Scholar] 619.Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D

The phase 3 TRIUMPH-4 trial confirmed these findings

Crafted with a meticulous blend of potent ingredients, MB System includes acacia, lemon bioflavonoids, and hesperidin to support overall wellness

Mass spectra analysis reveals molecular weights and fragmentation patterns, enabling detection of impurities like oxidation products and deamidated peptides